[withdrawn] efgartigimod alfa in the treatment of myasthenia gravis (gmg)

Decision EFGARTIGIMOD ALFA IN THE TREATMENT OF MYASTHENIA GRAVIS (GMG) EAMS scientific opinion issued to argenx BV for efgartigimod alpha to treat adults with generalised Myasthenia Gravis

(gMG), an autoimmune disease that causes muscle weakness. gMG can affect multiple muscle groups throughout the body. Get emails about this page THIS PUBLICATION WAS WITHDRAWN ON 31 MARCH

2023 Reason: Granting of marketing authorisation DOCUMENTS WITHDRAWN - EFGARTIGIMOD ALFA - PUBLIC ASSESSMENT REPORT (PAR) PDF, 721 KB, 3 pages This file may not be suitable for users of

assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email

[email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use. EFGARTIGIMOD ALFA - TREATMENT PROTOCOL INFORMATION FOR PATIENTS

PDF, 163 KB, 5 pages This file may not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a

version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

EFGARTIGIMOD ALFA - TREATMENT PROTOCOL INFORMATION FOR HEALTHCARE PROFESSIONALS PDF, 243 KB, 11 pages This file may not be suitable for users of assistive technology. Request an accessible

format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what

format you need. It will help us if you say what assistive technology you use. EFGARTIGIMOD ALFA - INFORMATION FOR NHS MEDICAL DIRECTOR PDF, 114 KB, 4 pages This file may not be suitable for

users of assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format,

please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use. EFGARTIGIMOD ALFA - TREATMENT PROTOCOL INFORMATION ON

THE PHARMACOVIGILANCE SYSTEM PDF, 152 KB, 4 pages This file may not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology (such as a

screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what

assistive technology you use. DETAILS For the full EAMS indication please see section 4.1 of the Treatment protocol: Information for healthcare professionals. The scientific opinion

includes: * a public assessment report (PAR) * a treatment protocol: * for healthcare professionals * for patients * on the pharmacovigilance system * Information for NHS Medical Directors

INFORMATION AND DETAILS REGARDING PATIENT ACCESS For new patients wishing to access EAMS medicines in England, trusts must register patients on the NHS England web-based registration system.

Queries to NHS England regarding the scheme can be submitted to [email protected]. For information about access in Northern Ireland, contact Chief Pharmaceutical Officer and

[email protected]. For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care at [email protected] For

information about access in Wales, contact the Welsh Government Health and Social Services Group by emailing Andrew Evans, Chief Pharmaceutical Officer or Lynne Schofield, Head of Pharmacy

and Prescribing policy at [email protected] UPDATES TO THIS PAGE Published 27 May 2022 SIGN UP FOR EMAILS OR PRINT THIS PAGE Get emails about this page Print this page